Arindam Talukdar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arindam Talukdar has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Sourav Pal
Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, WB, India
10 shared publicationsAyan Mukherjee
Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, WB, India
8 shared publicationsBarnali Paul
Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, WB, India
8 shared publicationsBiswajit Kundu
Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata, 700032, WB, India
8 shared publicationsDipyaman Ganguly
IICB-Translational Research Unit of Excellence, Department of Cancer Biology and Inflammatory Disorders, CSIR-Indian Institute of Chemical Biology, CN6, Sector V, Salt Lake, Kolkata, 700091, WB, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
8 shared publicationsSwarnali Roy
Department of Organic and Medicinal Chemistry, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Kolkata 700032, West Bengal, India
8 shared publications
Latest Publications
- Open Access
Discovery of a Small-Molecule mTORC1 Pathway Activator that Enhances Adoptive T-Cell Therapy via Immuno-metabolic Reprogramming of CD8 + T Cells
Adoptive cell therapy (ACT) has transformed cancer immunotherapy; however, its clinical efficacy remains limited by progressive T cell dysfunction and inadequate metabolic fitness acquired during ex vivo expansion and within the tumor microenvironment. Here, we report the discovery of AS-3, a first-in-class small-molecule activator that enhances the therapeutic competence of CD8⁺ T cells through RAPTOR-dependent mTORC1 activation. Identified by phenotypic screening of an in-house library of pharmacologically relevant scaffolds and subsequent medicinal chemistry optimization, AS-3 markedly increased effector cytokine production while preserving T cell viability. Mechanistically, AS-3 enhanced phosphorylation of mTORC1 downstream effectors, promoted glycolytic and mitochondrial metabolism, and sustained pathway activity under rapamycin-mediated inhibition. Transcriptomic profiling of activated human CD8⁺ T cells revealed coordinated enrichment of mTORC1 signalling, oxidative phosphorylation, glycolysis, proliferative programs, and cytotoxic effector gene networks, consistent with comprehensive immunometabolic reprogramming. Genetic silencing of RAPTOR attenuated both mTORC1 signalling and cytokine induction, establishing pathway dependency. Ex vivo conditioning with AS-3 significantly improved antitumor efficacy in two independent adoptive T-cell therapy models, accompanied by enhanced persistence, reduced exhaustion, and superior effector function. Together, these findings establish pharmacological activation of the RAPTOR-mTORC1 axis as a strategy to generate metabolically resilient T cells and provide a clinically translatable approach to improving the durability and efficacy of next-generation ACT.
Open AccessDiscovery of a Small-Molecule mTORC1 Pathway Activator that Enhances Adoptive T-Cell Therapy via Immuno-metabolic Reprogramming of CD8 + T Cells
Adoptive cell therapy (ACT) has transformed cancer immunotherapy; however, its clinical efficacy remains limited by progressive T cell dysfunction and inadequate metabolic fitness acquired during ex vivo expansion and within the tumor microenvironment. Here, we report the discovery of AS-3, a first-in-class small-molecule activator that enhances the therapeutic competence of CD8⁺ T cells through RAPTOR-dependent mTORC1 activation. Identified by phenotypic screening of an in-house library of pharmacologically relevant scaffolds and subsequent medicinal chemistry optimization, AS-3 markedly increased effector cytokine production while preserving T cell viability. Mechanistically, AS-3 enhanced phosphorylation of mTORC1 downstream effectors, promoted glycolytic and mitochondrial metabolism, and sustained pathway activity under rapamycin-mediated inhibition. Transcriptomic profiling of activated human CD8⁺ T cells revealed coordinated enrichment of mTORC1 signalling, oxidative phosphorylation, glycolysis, proliferative programs, and cytotoxic effector gene networks, consistent with comprehensive immunometabolic reprogramming. Genetic silencing of RAPTOR attenuated both mTORC1 signalling and cytokine induction, establishing pathway dependency. Ex vivo conditioning with AS-3 significantly improved antitumor efficacy in two independent adoptive T-cell therapy models, accompanied by enhanced persistence, reduced exhaustion, and superior effector function. Together, these findings establish pharmacological activation of the RAPTOR-mTORC1 axis as a strategy to generate metabolically resilient T cells and provide a clinically translatable approach to improving the durability and efficacy of next-generation ACT.
- 16 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 304, 118462
Targeted screening and rational optimization of bazedoxifene analogs as pan-variant SARS-CoV-2 entry inhibitors with improved pharmacokinetics
- 16 December 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 304, 118462
Targeted screening and rational optimization of bazedoxifene analogs as pan-variant SARS-CoV-2 entry inhibitors with improved pharmacokinetics
- 10 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118224
Benzoxaboroles in medicinal chemistry: A structure-guided perspective on next-generation therapeutics
- 10 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 301, 118224
Benzoxaboroles in medicinal chemistry: A structure-guided perspective on next-generation therapeutics
- 6 June 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (8) , 3469-3494
Rational design and discovery of potent PROTAC degraders of ASK1: a targeted therapy in MASH
The first PROTAC degrader of ASK1, dASK1-VHL (60), was rationally designed and validated via in vitro assays and PK studies, demonstrating therapeutic efficacy in an MCD diet-induced MASH mouse model, underscoring its promise in metabolic diseases.
- 6 June 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (8) , 3469-3494
Rational design and discovery of potent PROTAC degraders of ASK1: a targeted therapy in MASH
The first PROTAC degrader of ASK1, dASK1-VHL (60), was rationally designed and validated via in vitro assays and PK studies, demonstrating therapeutic efficacy in an MCD diet-induced MASH mouse model, underscoring its promise in metabolic diseases.
- 23 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9371-9406
Strategic Design and Optimization of Umifenovir Analogues: Balancing Antiviral Efficacy and hERG Toxicity against SARS-CoV-2
Arbidol (ARB, Umifenovir), a broad-spectrum antiviral from Russia, lacks Food and Drug Administration (FDA) approval due to insufficient clinical data and undocumented toxicity concerns. Its indole scaffold, with six unique substitutions, enables optimization for improved efficacy. This study optimized ARB's antiviral potency and safety by modifying the N1, C2, C3, and C4 positions. Antiviral efficacy was evaluated in SARS-CoV-2-infected VERO E6 cells, while optimization was guided by absorption, distribution, metabolism, and excretion (ADME), in vivo pharmacokinetic (PK) and hERG. Early modifications at N1 and C2 produced compounds 10 and 14 (IC50 = 1.5 μM), surpassing ARB (IC50 = 9.0 μM). Further refinements yielded compounds 42 (IC50 = 1.1 μM) and 56 (IC50 = 0.24 μM), resolving hERG toxicity (>30 μM). C3 modifications led to lead compounds 77, 79, and 81 (IC50 = 0.67-0.7 μM), achieving superior potency while eliminating hERG toxicity. Mechanism of entry inhibition and immunofluorescence confirmed compound 77 significantly reduced SARS-CoV-2 within Vero cells, supporting their preclinical potential.
- 23 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9371-9406
Strategic Design and Optimization of Umifenovir Analogues: Balancing Antiviral Efficacy and hERG Toxicity against SARS-CoV-2
Arbidol (ARB, Umifenovir), a broad-spectrum antiviral from Russia, lacks Food and Drug Administration (FDA) approval due to insufficient clinical data and undocumented toxicity concerns. Its indole scaffold, with six unique substitutions, enables optimization for improved efficacy. This study optimized ARB's antiviral potency and safety by modifying the N1, C2, C3, and C4 positions. Antiviral efficacy was evaluated in SARS-CoV-2-infected VERO E6 cells, while optimization was guided by absorption, distribution, metabolism, and excretion (ADME), in vivo pharmacokinetic (PK) and hERG. Early modifications at N1 and C2 produced compounds 10 and 14 (IC50 = 1.5 μM), surpassing ARB (IC50 = 9.0 μM). Further refinements yielded compounds 42 (IC50 = 1.1 μM) and 56 (IC50 = 0.24 μM), resolving hERG toxicity (>30 μM). C3 modifications led to lead compounds 77, 79, and 81 (IC50 = 0.67-0.7 μM), achieving superior potency while eliminating hERG toxicity. Mechanism of entry inhibition and immunofluorescence confirmed compound 77 significantly reduced SARS-CoV-2 within Vero cells, supporting their preclinical potential.
- 8 May 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (10) , 8225-8246
Exploring the Structural Attributes of Yoda1 for the Development of New-Generation Piezo1 Agonist Yaddle1 as a Vaccine Adjuvant Targeting Optimal T Cell Activation
Piezo1, a mechano-activated ion channel, has wide-ranging physiological and therapeutic implications, with the ongoing development of specific agonists unveiling cellular responses to mechanical stimuli. In our study, we systematically analyzed the chemical subunits in Piezo1 protein agonist Yoda1 to comprehend the structure-activity relationship and push forward next-generation agonist development. Preliminary screening assays for Piezo1 agonism were performed using the Piezo1-mCherry-transfected HEK293A cell line, keeping Yoda1 as a positive control. We introduce a novel Piezo1 agonist Yaddle1 (34, 0.40 μM), featuring a trifluoromethyl group, with further exploration through in vitro studies and density functional theory calculations, emphasizing its tetrel interactions, to act as an ambidextrous wedge between the domains of Piezo1. In contrast to the poor solubility of the established agonist Yoda1, our results showed that the kinetic solubility of Yaddle1 (26.72 ± 1.8 μM at pH 7.4) is 10-fold better than that of Yoda1 (1.22 ± 0.11 μM at pH 7.4). Yaddle1 (34) induces Ca2+ influx in human CD4+ T cell, suggesting its potential as a vaccine adjuvant for enhanced T cell activation.
- 8 May 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (10) , 8225-8246
Exploring the Structural Attributes of Yoda1 for the Development of New-Generation Piezo1 Agonist Yaddle1 as a Vaccine Adjuvant Targeting Optimal T Cell Activation
Piezo1, a mechano-activated ion channel, has wide-ranging physiological and therapeutic implications, with the ongoing development of specific agonists unveiling cellular responses to mechanical stimuli. In our study, we systematically analyzed the chemical subunits in Piezo1 protein agonist Yoda1 to comprehend the structure-activity relationship and push forward next-generation agonist development. Preliminary screening assays for Piezo1 agonism were performed using the Piezo1-mCherry-transfected HEK293A cell line, keeping Yoda1 as a positive control. We introduce a novel Piezo1 agonist Yaddle1 (34, 0.40 μM), featuring a trifluoromethyl group, with further exploration through in vitro studies and density functional theory calculations, emphasizing its tetrel interactions, to act as an ambidextrous wedge between the domains of Piezo1. In contrast to the poor solubility of the established agonist Yoda1, our results showed that the kinetic solubility of Yaddle1 (26.72 ± 1.8 μM at pH 7.4) is 10-fold better than that of Yoda1 (1.22 ± 0.11 μM at pH 7.4). Yaddle1 (34) induces Ca2+ influx in human CD4+ T cell, suggesting its potential as a vaccine adjuvant for enhanced T cell activation.
- 27 February 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 269, 116256
Hit-to-lead optimization of 2-aminoquinazolines as anti-microbial agents against Leishmania donovani
- 27 February 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 269, 116256
Hit-to-lead optimization of 2-aminoquinazolines as anti-microbial agents against Leishmania donovani
- 15 December 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (24) , 16728-16761
Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis
E3 ubiquitin ligase, Constitutive Photomorphogenic 1 (COP1) regulates turnover of Adipose Triglyceride Lipase (ATGL), the rate-limiting lipolytic enzyme. Genetic perturbation in the COP1-ATGL axis disrupts lipid homeostasis, leading to liver steatosis. Using drug development strategies, we herein report quinazolinone and quinazolinedione based modulators for COP1-ATGL axis. Systematic SAR studies and subsequent optimization were performed by incorporating relevant functional groups at the N1, N3, C5, and C6 positions of both scaffolds. Compounds' efficacy was evaluated by multiple biological assays and ADME profiling. The lead compound 86 could increase ATGL protein expression, reduce ATGL ubiquitination and COP1 autoubiquitination, and diminish lipid accumulation in hepatocytes in the nanomolar range. Oral administration of 86 abrogated triglyceride accumulation and resolved fibrosis in preclinical Nonalcoholic Fatty Liver Disease (NAFLD) model. The study thus establishes quinazolinedione as a viable chemotype to therapeutically modulate the activity of COP1 and ATGL in relevant clinical contexts.
- 15 December 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (24) , 16728-16761
Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis
E3 ubiquitin ligase, Constitutive Photomorphogenic 1 (COP1) regulates turnover of Adipose Triglyceride Lipase (ATGL), the rate-limiting lipolytic enzyme. Genetic perturbation in the COP1-ATGL axis disrupts lipid homeostasis, leading to liver steatosis. Using drug development strategies, we herein report quinazolinone and quinazolinedione based modulators for COP1-ATGL axis. Systematic SAR studies and subsequent optimization were performed by incorporating relevant functional groups at the N1, N3, C5, and C6 positions of both scaffolds. Compounds' efficacy was evaluated by multiple biological assays and ADME profiling. The lead compound 86 could increase ATGL protein expression, reduce ATGL ubiquitination and COP1 autoubiquitination, and diminish lipid accumulation in hepatocytes in the nanomolar range. Oral administration of 86 abrogated triglyceride accumulation and resolved fibrosis in preclinical Nonalcoholic Fatty Liver Disease (NAFLD) model. The study thus establishes quinazolinedione as a viable chemotype to therapeutically modulate the activity of COP1 and ATGL in relevant clinical contexts.
- 10 August 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (16) , 10868-10877
Catalyzing the Future of Medicinal Chemistry Research in India
The present publication provides a comprehensive look at more than a decade (2010 to midyear of 2023) of medicinal chemistry research in India, focusing on contributions to medicinal chemistry and drug discovery from both Indian academia and industries. The work provides an overview of cutting-edge medicinal chemistry research along with the organic-transformation-based chemical research scenarios in India in the past decade. It also distinguishes areas of research as well as contributions from different federal research institutes, state universities, central universities, and private universities by their geographical locations around India. The paper takes broader stock of the situation by comparing the articles published in the two internationally acclaimed journals in the field, viz. Journal of Medicinal Chemistry and Organic Letters, which highlights the current research trends as well as the thrust needed at the grass-roots level to boost medicinal chemistry and drug discovery research in India. Finally, we believe that this discussion may create a pathway for policymakers and funding agencies to focus their efforts to motivate lesser inclined institutions as well as provide incentives to the institutions primarily involved in medicinal chemistry research, as they already have built capacity for such research.
- 10 August 2023
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (16) , 10868-10877
Catalyzing the Future of Medicinal Chemistry Research in India
The present publication provides a comprehensive look at more than a decade (2010 to midyear of 2023) of medicinal chemistry research in India, focusing on contributions to medicinal chemistry and drug discovery from both Indian academia and industries. The work provides an overview of cutting-edge medicinal chemistry research along with the organic-transformation-based chemical research scenarios in India in the past decade. It also distinguishes areas of research as well as contributions from different federal research institutes, state universities, central universities, and private universities by their geographical locations around India. The paper takes broader stock of the situation by comparing the articles published in the two internationally acclaimed journals in the field, viz. Journal of Medicinal Chemistry and Organic Letters, which highlights the current research trends as well as the thrust needed at the grass-roots level to boost medicinal chemistry and drug discovery research in India. Finally, we believe that this discussion may create a pathway for policymakers and funding agencies to focus their efforts to motivate lesser inclined institutions as well as provide incentives to the institutions primarily involved in medicinal chemistry research, as they already have built capacity for such research.
- 10 August 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 260, 115713
Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach
- 10 August 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 260, 115713
Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach